Will have do a lot more research of the above to fully understand the science above (learning curve will be a barrier to attract new PYC investors),
I guess our book has roughly the same ending; $10B by 2025; if PYC can execute promised milestones - delivering 3 blockbuster drugs to market; VP-001 in 2025, VP-002 roughly ~2026, with CNS-001 close behind.
$10B will be a cheap market cap for a serial blockbuster drug creator; mr market could assign much more if he accretes value to PYC dual RNA therapeutics platform - more than it’s current 5% probability anyway… But I don’t think mr market understands PYC science as well as the key contributors on this thread
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)